UNSPSC 51282131: Hetacillin potassium

This classification denotes a penicillin antibiotic C19H22N3O4S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95PFX5932Y, chemically known as potassium 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, but more generally known as hetacillin potassium, which bears US NIH Compound Identifier 23677959. European Medicines Agency schedules Hetacillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02502MIG.

UNSPSC 51282131 Hetacillin potassium, a Commodity code, shows significant mismatch between its nominal scope and recent state and local solicitation activity. The code nominally designates a specific pharmaceutical compound—hetacillin potassium, a beta-lactam antibiotic—yet the recent opportunities indexed under it span naloxone procurement, direct-to-manufacturer pharmacy initiatives, emergency medical supplies for fire rescue operations, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing. These solicitations reflect actual state and local health and safety purchasing, but hetacillin potassium itself does not appear in any of the four most recent opportunities posted under this code. The code shows little relevant recent activity for vendors positioned to supply the specific pharmaceutical named in the UNSPSC designation.

The issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Recent opportunities span an RFI from Texas HHS posted April 3, 2026, a competitive bid from the City of Tampa due March 13, 2026 for $700,000 in medical and first aid supplies for fire rescue operations, an MMCAP RFP for generic pharmaceuticals and OTC products due March 26, 2026, and an IFB from Seminole County posted June 30, 2026 for naloxone and drug deactivation systems with a July 26, 2023 deadline. Activity appears concentrated in Florida and the upper Midwest, with Texas participating in exploratory market research. Vendors seeking hetacillin potassium procurement specifically should note that this code's recent activity does not reflect demand for the compound itself; pursuing opportunities would require repositioning to broader pharmaceutical, medical supply, or pharmacy benefit management categories.